NCT03919656View on ClinicalTrials.gov

SGLT-2 Inhibition, Metabolomics and Cardiovascular/Kidney Disease

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 12, 2019

Primary Completion Date

January 12, 2024

Study Completion Date

May 23, 2024

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Dapagliflozin 10 mg

Dapagliflozin 10 mg daily in a green, plain, diamond shaped, film coated tablet (orally)

DRUG

Placebo Oral Tablet

Green, plain, diamond shaped, film coated tablet (orally). Does not contain active ingredient

Trial Locations (1)

29010

Virgen de la Victoria University Hospital. Endocrinology Department, Málaga

All Listed Sponsors
lead

Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud

OTHER

NCT03919656 - SGLT-2 Inhibition, Metabolomics and Cardiovascular/Kidney Disease | Biotech Hunter | Biotech Hunter